Can TZDs cause hypoglycemia?

Conclusions: Common side effects associated with TZDs include edema, weight gain, macular edema and heart failure. Moreover, they may cause hypoglycemia when combined with other antidiabetic drugs as well as decrease hematocrit and hemoglobin levels. Increased bone fracture risk is another TZD-related side effect.

How do thiazolidinediones lower blood sugar?

Thiazolidinediones (TZDs), also known as glitazones, are a type of medication that people with type 2 diabetes can use to lower blood sugar levels by reducing insulin resistance.

When used as a monotherapy thiazolidinediones will promote hypoglycemia?

6.4. 5.6 Advantages. Thiazolidinediones, when used as monotherapy, are not associated with hypoglycemia, as they do not increase insulin secretion.

What is a metabolic effect that may occur with taking thiazolidinediones?

Metabolism. The thiazolidinediones can cause hypoglycemia both when used alone or in combination with other hypoglycemic drugs (47). The thiazolidinediones increase body weight.

Why are TZDs contraindicated in heart failure?

The mechanism of heart failure due to the thiazolidinediones is via fluid retention (Figure 1). Both these agents act on renal peroxisome proliferator-activated receptor gamma (PPAR gamma) and lead to increased sodium retention, fluid retention, and consequent heart failure among persons with diabetes.

Can meglitinides cause hypoglycemia?

The use of meglitinides increased the risk of hypoglycemia (HR, 1.94, p<0.001), as did other anti-diabetic agents. Concomitant use of meglitinide and insuilin will incresase the hypoglycemic risk.

What are the side effects of thiazolidinediones Mcq?

Side effects

• water retention.
• weight gain.
• eyesight problems.
• reduced sense of touch.
• chest pain and infections.
• allergic skin reactions.

Can Meglitinides cause hypoglycemia?

Why do TZDs cause edema?

TZDs may interact synergistically with insulin to cause arterial vasodilatation, leading to sodium reabsorption with a subsequent increase in extracellular volume, and thereby resulting in pedal edema.

How does the meglitinides differ from the sulfonylureas?

Meglitinides (eg, repaglinide, nateglinide) are much shorter-acting insulin secretagogues than the sulfonylureas are, with preprandial dosing potentially achieving more physiologic insulin release and less risk for hypoglycemia.

Are sulfonylureas and meglitinides the same?

Meglitinides are secretagogues like sulfonylureas, although not structurally related. They induce insulin secretion from pancreas, with a different mechanism of action from sulfonylureas.